BioMarin Strikes Gene Therapy Partnership Targeting Rare Genetic Cardiomyopathies

BioMarin Pharmaceutical Inc. BMRN is beefing up its gene therapy portfolio. 

The large-cap biopharma BioMarin said it has entered into a pre-clinical collaboration and licensing agreement with DiNAQOR, a gene therapy platform company headquartered in Switzerland, to develop gene therapies to treat rare genetic cardiomyopathies.

The licensing agreement will initially cover DiNAQOR's lead candidate DiNA-001, which is being evaluated for MYBPC3 hypertrophic cardiomyopathy, or HCM.

HCM is one of the most common genetic heart diseases, with about 500,000 patients diagnosed, and up to 60% of HCM cases have a genetic origin, BioMarin said.

It is estimated that 40% of those have mutations in MYBPC3, the gene that encodes cardiac myosin-binding protein C, the company said. 

HCM affects the heart muscle, often increasing the risk of heart failure and life-threatening arrhythmias, and there is no currently available pharmacologic treatment option for the disease.

BioMarin, which itself is speculated to be an M&A target, said it has the option to extend the license to include DiNAQOR's other pipeline programs on similar terms.

BioMarin said it is also picking up a stake in DiNAQOR.

The financial terms of the deal were not disclosed.

BioMarin also reiterated its 2020 GAAP net income guidance of $20 million to $80 million, after factoring in this collaboration.

"With this agreement, BioMarin is continuing to apply its gene therapy know-how and manufacturing expertise in new areas like cardiology," BioMarin CEO Jean-Jacques Bienaimé said in a statement. 

BioMarin's BLA for AAV5 gene therapy candidate valoctocogene roxaparvovec has been accepted for review by the FDA with a priority review designation. The gene therapy, which is being evaluated for a bleeding disorder, has a PDUFA action date of Aug. 21.

BioMarin shares were down 1.44% at $86.85 at the time of publication Monday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsContractsTrading IdeasDiNAQORgene therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!